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Abstract Previous studies from this laboratory have shown that
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
(HCRI) causes apoptotic cell death of a muscle cell-derived cell
line, L6 myoblasts, by involving the phosphatidylinositol-3 (PI-3)
kinase pathway and tyrosine phosphorylation of several cellular
proteins, although the relationship between PI-3 kinase pathway
and tyrosine phosphorylation responses remained to be eluci-
dated. Here, we show that HCRI induces tyrosine phosphoryla-
tion of catalytic subunit p110 of PI-3 kinase as early as 5 min
after addition of HCRI into culture medium. We could not detect
the tyrosine phosphorylation of the regulatory subunit p85 of
PI-3 kinase under the present experimental conditions. Concomi-
tantly, the kinase activity toward PI in p110 immunoprecipitates
was decreased with a similar time course. Furthermore, both
herbimycin A and genistein, potent inhibitors of tyrosine kinase
activity, inhibited HCRI-induced inhibition of PI-3 kinase
activity as well as HCRI-induced apoptotic cell death. Once
the catalytic subunit p110 becomes tyrosine-phosphorylated, the
regulatory subunit p85 appears to be dissociated from the
catalytic subunit, because we observed a decreasing amount of
p85 regulatory subunits in p110 immunoprecipitates in response
to HCRI treatment. These results strongly suggest the novel
function of tyrosine phosphorylation of catalytic subunit p110 of
PI-3 kinase in the regulation of its kinase activity. The tyrosine
phosphorylation of these catalytic subunits may play an
important role in the intracellular signal transduction of
apoptotic cell death. To our knowledge, this is the first report
that tyrosine phosphorylation of p110 catalytic subunit acts as a
negative regulator of its kinase activity. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase is a rate-limiting enzyme for the production of cho-
lesterol and its inhibitor (HCRI) is now widely used for the
treatment of hypercholesterolemia [1,2]. HCRI catalyzes the
conversion of HMG-CoA to mevalonate that is an important
precursor of all isoprenoids. Isoprenoids serve as an impor-
tant lipid for the normal translational modi¢cation of the
membrane-associated proteins such as Ras and Rho. It has
been reported that HCRI exerts adverse e¡ects such as myo-
pathy, rhabdomyolysis, suicidal tendency, and neurosis [3^7].
Our previous studies have shown that some HCRIs provoked
apoptotic cell death of a muscle cell-derived cell line, L6 myo-
blasts in culture, which is involved in tyrosine phosphoryla-
tion of several cellular proteins and the phosphatidylinositol-3
(PI-3) kinase-dependent pathway [8,9]. HCRI induced tyro-
sine phosphorylation of several cellular proteins and this ty-
rosine phosphorylation seemed to act as a positive signal
transducer for apoptotic cell death in L6 myoblasts, because
tyrosine kinase inhibitors such as herbimycin A and genistein
prevent HCRI-induced cell death [8]. In the follow up study,
we identi¢ed one of these tyrosine-phosphorylated target pro-
teins as phospholipase Q1 [10]. On the other hand, we also
examined the possible involvement of the Ras-dependent
pathway in HCRI-induced apoptotic cell death, because as
described above HCRI is reported to inhibit the production
of isoprenoid derivatives in addition to cholesterol synthesis
[11]. Ras protein is known to be isoprenylated and anchored
to the plasma membrane to do its job during many cellular
events. We found that HCRI indeed prevented normal matu-
ration of Ras protein and it induced the inhibition of PI-3
kinase activity of the Ras-bound form resulting in the trans-
location of its kinase activity from membrane fraction to cy-
tosolic fraction, which has been reported to be one of the
most important anti-apoptotic signal transducers in several
cell systems [9].
PI-3 kinase is a cytosolic heterodimerized protein consisting
of p110 catalytic subunit (K and L isoforms) and p85 regula-
tory subunit (K and L isoforms). It catalyzes the formation of
the family of phosphoinositides with phosphate at the D-3
position of the inositol ring [12^14]. This kinase contains sev-
eral motifs by which it can associate with cytoplasmic tyrosine
kinase receptors or membrane-bound receptor-type tyrosine
kinases forming signaling complexes. Although the entire
scheme of the mechanism of the activation of this kinase
activity still remained to be extensively studied, several mech-
anisms of the activation have been reported. One mechanism
is a small GTP-binding protein, Ras protein-dependent path-
way. PI-3 kinase can be associated with the active form of the
Ras protein, which results in the activation of its kinase ac-
tivity [15]. It could be due to an allosteric activation by its
binding to the Ras protein. The other is the association with
activated receptor-type tyrosine kinase through SH-2 domain
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of the p85 regulatory subunit. SH-2 domain-mediated binding
of PI-3 kinase to multiple receptors has been demonstrated for
the platelet-derived growth factor receptor [16], CD28 [17],
and interleukin-2 receptor [18]. This type of association is
known to help this enzyme to be translocated near its lipid
substrates and to result in the activation of PI-3 kinase activ-
ity. Furthermore, the primary amino acid sequences of the
p85 and p110 subunits also show several putative sites for
tyrosine phosphorylation [12,19,20]. A direct relationship be-
tween the tyrosine phosphorylation of PI-3 kinase (p85 or
p110 subunits) and an activation of its kinase activity, how-
ever, has not been clearly demonstrated. A recent report by
Mazerolles and Fisher demonstrated that binding of CD4 li-
gands induces tyrosine phosphorylation of PI-3 kinase p110
subunit, although they did not address the role of tyrosine
phosphorylation of p110 subunit of PI-3 kinase in the regu-
lation of the kinase activity [21].
Here, we show that HCRI induces a tyrosine phosphoryla-
tion of the p110 catalytic subunit of PI-3 kinase but not p85
regulatory subunit resulting in the inhibition of PI-3 kinase
activity. Furthermore, once the p110 subunit of PI-3 kinase
gets tyrosine-phosphorylated, p85 subunit seems to become
dissociated from p110 subunit. This dissociation of p110
from p85 subunit could result in the abnormal translocation
of PI-3 kinase from the membrane to the cytosolic fraction.
2. Materials and methods
2.1. Cell culture and treatment
L6 myoblasts (a generous gift from Dr. K. Nakahara, Kagoshima
University School of Medicine, Kagoshima, Japan) were cultured as
monolayers in culture dishes with Dulbecco’s modi¢ed Eagle’s me-
dium containing 7.5% fetal calf serum and 100 U/ml penicillin and
100 Wg/ml streptomycin [8^10]. Cells were treated with various con-
centrations of simvastatin (a generous gift from Sankyo Ltd., Tokyo,
Japan) for an appropriate period of time at 37‡C. Control sister cul-
tures were conducted in a similar way except for the absence of sim-
vastatin. In some case, cells were preincubated with 10 WM herbimycin
A (BioMol, USA) or genistein (75 WM) (Extrasynthese, France), po-
tent inhibitors of tyrosine kinase activity for 3 h before the addition of
simvastatin into culture medium as described previously [8].
2.2. Immunoprecipitation and immunoblot analysis
L6 myoblasts were exposed to 30 Wg/ml simvastatin for indicated
times. After stimulation with simvastatin, cells were rinsed brie£y with
chilled phosphate-bu¡ered saline (PBS) containing 1 mM p-nitrophe-
nylphosphate and lysed with a lysis bu¡er (20 mM HEPES, pH 7.2/
1% Nonidet P-40/10% glycerol/50 mM NaF/1 mM Na3VO4/10 Wg/ml
leupeptin) as described previously [22]. Non-speci¢c binding was elim-
inated by preclearing cell-free lysates with protein A-agarose in the
cold room for 1 h. The resultant supernatant (normally 1 mg/ml) was
used for the immunoprecipitation either with an anti-p110 catalytic
subunit of PI-3 kinase (K-p110, Santa Cruz Laboratories, USA) or
with an anti-p85 K regulatory subunit (K-p85, Santa Cruz Laborato-
ries, USA) as described previously [9]. These immunoprecipitates were
subjected to Western blotting and probed with an anti-phosphotyro-
sine antibody (K-PY, Upstate Biotechnology, Lake Placid, NY, USA),
K-p110, and K-p85 antibody. Detection of positive bands in the im-
munoblot was performed using the ECL detection kit (New England
Biolab, Inc., MA, USA). Protein concentration of cell-free lysate was
determined using the Bradford reagent (Bio-Rad, USA) with Q-glob-
ulin as a standard [23].
2.3. Measurement of PI-3 kinase activity in crude homogenates and
immunoprecipitates
PI-3 kinase activity was measured in crude homogenates and p110
immunoprecipitates using PI as a substrate as described previously [9].
Brie£y, crude cell homogenates or p110 immunoprecipitates were pre-
incubated in 50 Wl of the kinase reaction bu¡er at room temperature
for 10 min using PI as substrate. The assay is initiated by the addition
of 5 Wl of ATP solution (80 WM ATP and 2 mCi/ml [Q-32P]ATP) and
incubated at 30‡C for 20 min. The reaction was stopped by addition
of 100 Wl of chloroform^methanol^11.6 N HCl (50:100:1). After cen-
trifugation, the lower organic phase was taken for the analysis by thin
layer chromatography (TLC) on silica gel plates, which were devel-
oped in chloroform^methanol^2.5% ammonium hydroxide^water
(43:38:5:7, v/v/v/v). The plates were exposed to X-ray ¢lm at
370‡C. We scraped each spot from TLC plates and measured the
radioactivity by Cerenkov counting [9].
3. Results and discussion
3.1. PI-3 kinase activity in crude homogenates
L6 myoblasts were incubated with 30 Wg/ml simvastatin for
5 or 10 min. Then, the cells were harvested with chilled PBS
and were homogenized with 20 mM HEPES, pH 7.4, contain-
ing 137 mM NaCl, 0.1 mM sodium vanadate, 1 mM PMSF,
1 mM EDTA, and 1 mM EGTA. PI-3 kinase activity was
measured with PI as a substrate as described in Section 2.
Simvastatin caused an inhibition of PI-3 kinase activity in
crude homogenates as early as 5 min after its addition in
the culture medium (Fig. 1-I).
3.2. PI-3 kinase activity in K-p110 immunoprecipitates
Cells were treated with simvastatin (30 Wg/ml) and p110
subunit of PI-3 kinase was immunoprecipitated with K-p110.
The resultant p110 immunoprecipitates were subjected to PI-3
Fig. 1. E¡ects of simvastatin on PI-3 kinase activity in crude homo-
genates (I) and p110 immunoprecipitates (II). I: PI-3 kinase activity
in crude homogenates as prepared in Section 2 from cells cultured
in the presence (2: 5 min, 3: 10 min) or absence (1) of 30 Wg/ml
simvastatin. PI-3 kinase activity was measured with an equal
amount of protein samples as described in Section 2. II: (a) PI-3 ki-
nase activity in p110 immunoprecipitates prepared from cell-free ly-
sates obtained from cells treated with 30 Wg/ml simvastatin. PI-3 ki-
nase treated for 5 min (2) and 10 min (3) or untreated (1) was
assayed with PI as a substrate as described in Section 2. PIP repre-
sents PI phosphate. The radioactivity in each spot corresponding to
PIP obtained by Cerenkov counting was as follows: I-1, 887 þ 45
cpm; I-2, 412 þ 25 cpm; I-3; 221 þ 19 cpm; II-1, 359 þ 22 cpm; II-2,
185 þ 27 cpm; II-3, 102 þ 14 cpm (triplicate assay; mean þ S.D.). (b)
Immunoblot analysis of the same samples used for II-a probed with
K-PY to check tyrosine phosphorylation of p110 subunit. (c) West-
ern blot analysis of p110 immunoprecipitates used for II-b was re-
probed after stripping the ¢rst antibody (K-PY) with K-p110. Note
the equal amount p110 subunit protein present in each immunopre-
cipitate. (d) Immunoblot analysis of p110 immunoprecipitates pre-
pared from cells cultured in the presence of simvastatin was evident
with simvastatin treatment.
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kinase assay as described above. PI-3 kinase activity recovered
in p110 immunoprecipitates was decreased progressively by
simvastatin treatment with a similar time course to that in
crude homogenates (Fig. 1-IIa).
3.3. Tyrosine phosphorylation of p110 subunit of PI-3 kinase in
response to simvastatin treatment
p110 immunoprecipitates as prepared above were subjected
to immunoblot analysis with K-PY. p110 subunit of PI-3 ki-
nase was time-dependently tyrosine-phosphorylated in re-
sponse to simvastatin treatment (Fig. 1-IIb). There is no cor-
relation between time-dependent tyrosine phosphorylation
and the amount of protein present in each immunoprecipitate
(Fig. 1-IIc). We next examined the amount of p85 subunit of
PI-3 kinase in these immunoprecipitates. The result showed
progressive decrement of p85 protein in these immunoprecipi-
tates with the same time course of the reduction of the kinase
activity (Fig. 1-IId).
3.4. Tyrosine phosphorylation of p85 subunit of PI-3 kinase by
simvastatin treatment
We also examined whether or not p85 subunit of PI-3 ki-
nase is also tyrosine-phosphorylated in response to simvasta-
tin treatment. We immunoprecipitated p85 subunit from cell-
free lysates prepared from cells treated with simvastatin as
described above and these immunoprecipitates were immuno-
blotted with K-PY. The results showed that we could not
observe any tyrosine phosphorylation response of p85 subunit
to simvastatin treatment as shown in Fig. 2a,b.
3.5. E¡ects of tyrosine kinase inhibitors on simvastatin-induced
PI-3 kinase activity recovered in K-p110
immunoprecipitates
Then, we examined the e¡ects of tyrosine kinase inhibitors
on PI-3 kinase activity in p110 immunoprecipitates (Fig. 3).
Herbimycin A pretreatment caused a signi¢cant inhibition of
simvastatin-induced reduction of PI-3 kinase activity (Fig. 3).
Moreover, genistein, another tyrosine kinase inhibitor, also
gave the same results (Fig. 3). As reported previously, these
tyrosine kinase inhibitors also rescued the cells from apoptotic
cell death induced by simvastatin [8].
These results are consistent with the notion that tyrosine
phosphorylation of p110 subunit of PI-3 kinase negatively
regulates its kinase activity. This tyrosine phosphorylation
might also cause some change in the binding a⁄nity of
p110 subunits of PI-3 kinase to p85 subunit, resulting in the
dissociation of p85 from p110 subunit when p110 subunit is
tyrosine-phosphorylated induced by simvastatin treatment. As
mentioned earlier, tyrosine phosphorylation induced by PI-3
kinase p110 subunit can be induced by CD4 ligands binding
[21]. On the other hand, these authors speculated that tyrosine
phosphorylation of p110 subunit activates the kinase activity,
although they did not show any direct data on PI-3 kinase
activity. Although we do not know the reason for this dis-
crepancy at present, di¡erent tyrosine residues of p110 subunit
might be phosphorylated in response to di¡erent stimuli em-
ployed in each experiment. Moreover, they also presented the
data that this tyrosine phosphorylation of p110 subunit did
not cause any change in the association with p85 subunit
regulatory subunit of PI-3 kinase. On the contrary, we clearly
observed the dissociation of tyrosine-phosphorylated p110 in-
duced by simvastatin treatment from p85 subunit, although
there was no obvious tyrosine phosphorylation of p85 subunit
in both reports. Several reports have suggested that the acti-
vation of PI-3 kinase involves tyrosine phosphorylation [24^
26]. For example, it has been reported that treatment of pu-
ri¢ed bovine brain PI-3 kinase with tyrosine phosphatase de-
creases its kinase activity [24]. These reports have suggested
the positive role of tyrosine phosphorylation of PI-3 kinase in
the regulation of its activity. Therefore, the present data sug-
gest for the ¢rst time the negative role of tyrosine phosphor-
ylation of p110 subunit of PI-3 kinase in regulating the activ-
ity. The entire scheme of HCRI-induced apoptotic cell death
of L6 myoblasts is now apparent. HCRI treatment causes
tyrosine phosphorylation of several cellular proteins including
PLC-Q1 and PI-3 kinase, the latter of which in turn causes the
dissociation of p110 subunit from p85 regulatory subunit.
These sequential events would cause the decrement of PI-3
kinase activity in cells, which is well known to be the strong
Fig. 2. p85 regulatory subunit was not tyrosine-phosphorylated in
response to simvastatin treatment. L6 myoblasts were treated with
30 Wg/ml simvastatin for 5 min (2) and 10 min (3) or untreated (1).
Then, p85 subunit was immunoprecipitated with K-p85 (a) or K-PY
(b). Simvastatin treatment did not induce any tyrosine phosphoryla-
tion of p85 subunit of PI-3 kinase.
Fig. 3. PI-3 kinase activity in p110 immunoprecipitates prepared
from cells pretreated with tyrosine kinase inhibitors herbimycin A
(1, 2) and genistein (4, 5) as described in Section 2 and treated with
30 Wg/ml simvastatin for 10 min (1, 5, 6) or untreated (3). a: PI-3
kinase activity was measured with p110 immunoprecipitates as de-
scribed in Section 2. PIP indicates the product of the enzymatic ac-
tion of PI-3 kinase. The radioactivity in each PIP spot obtained by
Cerenkov counting was as follows: 1432 þ 14 cpm; 2428 þ 21 cpm;
3429 þ 25 cpm; 4456 þ 23 cpm; 5302 þ 19 cpm; 684 þ 33 cpm (dupli-
cate assay; mean þ S.D.). b: Western blot analysis of p110 immuno-
precipitates used for (a) probed with K-p110. Note the same amount
of p110 subunit protein present in each immunoprecipitate.
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anti-apoptotic signaling molecule. Further experiments need
to be performed to elucidate the exact site(s) of tyrosine phos-
phorylation in p110 subunit and the mechanism of the disso-
ciation of p85 subunit from the tyrosine-phosphorylated p110
subunit of PI-3 kinase.
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